Neostigmine and Atropine for the Treatment of Headache After Dural Puncture Placement

• Status: Not yet recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to evaluate Neostigmine and Atropine to treat post-dural puncture headache (PDPH) to reduce the proportion of postpartum women with a PDPH requiring epidural blood patch (EBP) who developed a PDPH after accidental dural puncture.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Atropine; Neostigmine

Criteria

Inclusion Criteria:

• Post-dural puncture headache (PDPH) after documented dural puncture with Tuohy needle during placement of epidural analgesia for labor and no other explanation for headache (HA).

• Onset of HA within 72 hours of delivery.

Exclusion Criteria:

• Patient refusal.

• Visual analog scale (NRS) score < 4.

• History of migraine headaches.

• Asthma.

• Arrhythmia.

• Heart block.

• Myasthenia gravis.

• Inability to understand pain scores and other questionnaires.

• Inability to speak English.

• Contraindication to acetaminophen or NSAIDs.

• Temperature > 38.5 C.

• Prior EBP done for this HA.